Pasithea Therapeutics Corp. (KTTA) Key Metrics
KTTA valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $14.0M
- Enterprise value
- −$28.7M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 42.2
- Price / book
- 0.3
- EV / EBITDA
- 2.9
- Dividend yield
- —
- Beta
- 0.34
KTTA key metrics, 2020–2025
Fiscal year ended December 31, 2025 · U.S. dollarsKTTA returns How much profit the business earns on the capital it uses.
KTTA financial health Debt, liquidity and how easily interest is covered.
KTTA valuation history
KTTA returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
KTTA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
KTTA cash returned to shareholders
KTTA price vs earnings per share
KTTA key metrics
2020–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| Market capitalization | $9.1M | — | — | — | — | — |
| Enterprise value | −$46.1M | — | — | — | — | — |
| Price / book | 0.2 | — | — | — | — | — |
| Earnings yield | −225.2% | — | — | — | — | — |
| Free cash flow yield | −167.7% | — | — | — | — | — |
| Share price at fiscal year-end | $1.29 | $3.15 | $7.40 | $12.84 | $35.40 | — |
| Per share | ||||||
| Revenue per share | $0.00 | — | — | — | — | — |
| Earnings per share | −$2.91 | — | — | — | — | — |
| Operating cash flow per share | −$2.16 | — | — | — | — | — |
| Free cash flow per share | −$2.16 | — | — | — | — | — |
| Cash per share | $7.85 | — | — | — | — | — |
| Book value per share | $7.85 | — | — | — | — | — |
| Tangible book value per share | $7.32 | — | — | — | — | — |
| Capex per share | $0.00 | — | — | — | — | — |
| Shares outstanding | 7.0M | — | — | — | — | — |
| Returns & profitability | ||||||
| Return on equity (ROE) | −58.4% | −72.8% | −48.4% | −29.7% | −8.4% | −25.5% |
| Return on invested capital (ROIC) | −416.1% | −150.0% | −148.0% | −237.7% | — | — |
| Return on assets (ROA) | −53.5% | −65.9% | −44.8% | −28.3% | −8.1% | −24.8% |
| Return on tangible assets | −36.2% | −185.6% | −94.4% | −39.4% | −4.1% | −24.8% |
| Financial health | ||||||
| Total debt | — | — | $81,680 | $504,383 | — | — |
| Cash & short-term investments | $55.2M | $6.9M | $16.3M | $33.1M | $53.0M | $243,650 |
| Net debt | −$55.2M | −$6.9M | −$16.2M | −$32.6M | −$53.0M | −$243,650 |
| Debt / equity | — | — | 0.00 | 0.01 | — | — |
| Debt / assets | — | — | 0.00 | 0.01 | — | — |
| Current ratio | 11.35 | 6.58 | 6.34 | 18.15 | 119.17 | 37.55 |
| Quick ratio | 11.35 | 6.58 | 6.35 | 18.15 | 119.17 | 37.55 |
| Working capital | $51.5M | $6.2M | $14.1M | $32.2M | $52.9M | $241,355 |
| Invested capital | $60,299 | $7.9M | $7.1M | $9.9M | −$1.5M | −$2,295 |
| Tangible asset value | $51.4M | $6.2M | $14.2M | $32.7M | $51.4M | $241,355 |
| Net current asset value | $51.4M | $6.1M | $14.0M | $31.4M | $51.4M | $241,355 |
| Graham net-net per share | $7.13 | — | — | — | — | — |
| Capital allocation | ||||||
| Dividends paid | — | $359.7M | — | — | — | — |
| Share buybacks (net) | — | $0 | $3.7M | $3.2M | $0 | — |
| Capex / revenue | — | — | 7.0% | 22.0% | 142.8% | — |
| Capex / depreciation | 0.00 | 0.00 | 0.05 | 21.03 | 15.59 | 0.00 |
| Stock-based compensation / revenue | — | — | 121.7% | 171.6% | 3,128.7% | — |
| R&D / revenue | — | — | 1,664.9% | 547.8% | — | — |
| SG&A / revenue | — | — | 1,619.2% | 2,039.5% | 29,911.0% | — |
| Efficiency | ||||||
| Days sales outstanding | — | — | 128.5 | 226.6 | — | — |
| Days of inventory on hand | — | — | -11.4 | 0.1 | — | — |
| Days payables outstanding | — | 1,032.6 | 1,135.3 | 69,097.5 | 4,795.0 | — |
| Cash conversion cycle (days) | — | — | -1,018.1 | -68,870.8 | — | — |
| Receivables turnover | — | — | 2.84 | 1.61 | — | — |
| Payables turnover | — | 0.35 | 0.32 | 0.01 | 0.08 | — |
| Inventory turnover | — | — | — | 5,094.00 | — | — |
| Asset turnover | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 |
| Average receivables | — | — | $171,316 | $302,132 | — | — |
| Average payables | — | $1.8M | $2.0M | $964,336 | $226,942 | $6,603 |
| Average inventory | — | — | −$20,250 | $1 | — | — |
| Intangibles / total assets | 6.3% | 53.4% | 35.2% | 21.8% | 0.0% | 0.0% |
Computed from KTTA's annual financial statements (latest annual report filed March 30, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
KTTA valuation and financial ratios
Pasithea Therapeutics earned a return on equity of −58.4% and a return on invested capital of −416.1% in fiscal 2025.
See the KTTA income statement, the KTTA chart for price history, or the KTTA stock overview for the latest quote and news.
KTTA key metrics FAQ
What is Pasithea Therapeutics's return on equity?
Pasithea Therapeutics's return on equity (ROE) was −58.4% in fiscal 2025: net income of -$20.4 million on average shareholders' equity of $35.0 million.
What is Pasithea Therapeutics's ROIC?
Pasithea Therapeutics's return on invested capital was −416.1% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
What is Pasithea Therapeutics's free cash flow yield?
Pasithea Therapeutics generated -$15.2 million of free cash flow in fiscal 2025, a free cash flow yield of −167.7% on its market value at year-end ($9.1 million).
What is Pasithea Therapeutics's current ratio?
Pasithea Therapeutics's current ratio was 11.35 at the end of fiscal 2025: current assets were 11.35 times current liabilities.